Antibodies to S2 domain of SARS-CoV-2 spike protein in Moderna mRNA vaccinated subjects sustain antibody-dependent NK cell-mediated cell cytotoxicity against Omicron BA.1
Vaccination with the primary two-dose series of SARS-CoV-2 mRNA protects against infection with the ancestral strain, and limits the presentation of severe disease after re-infection by multiple variants of concern (VOC), including Omicron, despite the lack of a strong neutralizing response to these...
Saved in:
Published in | Frontiers in immunology Vol. 14; p. 1266829 |
---|---|
Main Authors | , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Switzerland
Frontiers Media S.A
2023
|
Subjects | |
Online Access | Get full text |
ISSN | 1664-3224 1664-3224 |
DOI | 10.3389/fimmu.2023.1266829 |
Cover
Loading…
Abstract | Vaccination with the primary two-dose series of SARS-CoV-2 mRNA protects against infection with the ancestral strain, and limits the presentation of severe disease after re-infection by multiple variants of concern (VOC), including Omicron, despite the lack of a strong neutralizing response to these variants. We compared antibody responses in serum samples collected from mRNA-1273 (Moderna) vaccinated subjects to identify mechanisms of immune escape and cross-protection. Using pseudovirus constructs containing domain-specific amino acid changes representative of Omicron BA.1, combined with domain competition and RBD-antibody depletion, we showed that RBD antibodies were primarily responsible for virus neutralization and variant escape. Antibodies to NTD played a less significant role in antibody neutralization but acted along with RBD to enhance neutralization. S2 of Omicron BA.1 had no impact on neutralization escape, suggesting it is a less critical domain for antibody neutralization; however, it was as capable as S1 at eliciting IgG3 responses and NK-cell mediated, antibody-dependent cell cytotoxicity (ADCC). Antibody neutralization and ADCC activities to RBD, NTD, and S1 were all prone to BA.1 escape. In contrast, ADCC activities to S2 resisted BA.1 escape. In conclusion, S2 antibodies showed potent ADCC function and resisted Omicron BA.1 escape, suggesting that S2 contributes to cross-protection against Omicron BA.1. In line with its conserved nature, S2 may hold promise as a vaccine target against future variants of SARS-CoV-2. |
---|---|
AbstractList | Vaccination with the primary two-dose series of SARS-CoV-2 mRNA protects against infection with the ancestral strain, and limits the presentation of severe disease after re-infection by multiple variants of concern (VOC), including Omicron, despite the lack of a strong neutralizing response to these variants. We compared antibody responses in serum samples collected from mRNA-1273 (Moderna) vaccinated subjects to identify mechanisms of immune escape and cross-protection. Using pseudovirus constructs containing domain-specific amino acid changes representative of Omicron BA.1, combined with domain competition and RBD-antibody depletion, we showed that RBD antibodies were primarily responsible for virus neutralization and variant escape. Antibodies to NTD played a less significant role in antibody neutralization but acted along with RBD to enhance neutralization. S2 of Omicron BA.1 had no impact on neutralization escape, suggesting it is a less critical domain for antibody neutralization; however, it was as capable as S1 at eliciting IgG3 responses and NK-cell mediated, antibody-dependent cell cytotoxicity (ADCC). Antibody neutralization and ADCC activities to RBD, NTD, and S1 were all prone to BA.1 escape. In contrast, ADCC activities to S2 resisted BA.1 escape. In conclusion, S2 antibodies showed potent ADCC function and resisted Omicron BA.1 escape, suggesting that S2 contributes to cross-protection against Omicron BA.1. In line with its conserved nature, S2 may hold promise as a vaccine target against future variants of SARS-CoV-2. Vaccination with the primary two-dose series of SARS-CoV-2 mRNA protects against infection with the ancestral strain, and limits the presentation of severe disease after re-infection by multiple variants of concern (VOC), including Omicron, despite the lack of a strong neutralizing response to these variants. We compared antibody responses in serum samples collected from mRNA-1273 (Moderna) vaccinated subjects to identify mechanisms of immune escape and cross-protection. Using pseudovirus constructs containing domain-specific amino acid changes representative of Omicron BA.1, combined with domain competition and RBD-antibody depletion, we showed that RBD antibodies were primarily responsible for virus neutralization and variant escape. Antibodies to NTD played a less significant role in antibody neutralization but acted along with RBD to enhance neutralization. S2 of Omicron BA.1 had no impact on neutralization escape, suggesting it is a less critical domain for antibody neutralization; however, it was as capable as S1 at eliciting IgG3 responses and NK-cell mediated, antibody-dependent cell cytotoxicity (ADCC). Antibody neutralization and ADCC activities to RBD, NTD, and S1 were all prone to BA.1 escape. In contrast, ADCC activities to S2 resisted BA.1 escape. In conclusion, S2 antibodies showed potent ADCC function and resisted Omicron BA.1 escape, suggesting that S2 contributes to cross-protection against Omicron BA.1. In line with its conserved nature, S2 may hold promise as a vaccine target against future variants of SARS-CoV-2.Vaccination with the primary two-dose series of SARS-CoV-2 mRNA protects against infection with the ancestral strain, and limits the presentation of severe disease after re-infection by multiple variants of concern (VOC), including Omicron, despite the lack of a strong neutralizing response to these variants. We compared antibody responses in serum samples collected from mRNA-1273 (Moderna) vaccinated subjects to identify mechanisms of immune escape and cross-protection. Using pseudovirus constructs containing domain-specific amino acid changes representative of Omicron BA.1, combined with domain competition and RBD-antibody depletion, we showed that RBD antibodies were primarily responsible for virus neutralization and variant escape. Antibodies to NTD played a less significant role in antibody neutralization but acted along with RBD to enhance neutralization. S2 of Omicron BA.1 had no impact on neutralization escape, suggesting it is a less critical domain for antibody neutralization; however, it was as capable as S1 at eliciting IgG3 responses and NK-cell mediated, antibody-dependent cell cytotoxicity (ADCC). Antibody neutralization and ADCC activities to RBD, NTD, and S1 were all prone to BA.1 escape. In contrast, ADCC activities to S2 resisted BA.1 escape. In conclusion, S2 antibodies showed potent ADCC function and resisted Omicron BA.1 escape, suggesting that S2 contributes to cross-protection against Omicron BA.1. In line with its conserved nature, S2 may hold promise as a vaccine target against future variants of SARS-CoV-2. |
Author | Cheng, Ying Qiu, Qi Letizia, Andrew G. Jenkins, Sarah A. Hontz, Robert D. Long, Tran Khanh Zhang, Zhiwen Corson, Karen S. Sun, Peifang Martin, Nicholas J. Schilling, Megan A. Balinsky, Corey A. Jiang, Le Belinskaya, Tatyana Jani, Vihasi |
Author_xml | – sequence: 1 givenname: Corey A. surname: Balinsky fullname: Balinsky, Corey A. – sequence: 2 givenname: Le surname: Jiang fullname: Jiang, Le – sequence: 3 givenname: Vihasi surname: Jani fullname: Jani, Vihasi – sequence: 4 givenname: Ying surname: Cheng fullname: Cheng, Ying – sequence: 5 givenname: Zhiwen surname: Zhang fullname: Zhang, Zhiwen – sequence: 6 givenname: Tatyana surname: Belinskaya fullname: Belinskaya, Tatyana – sequence: 7 givenname: Qi surname: Qiu fullname: Qiu, Qi – sequence: 8 givenname: Tran Khanh surname: Long fullname: Long, Tran Khanh – sequence: 9 givenname: Megan A. surname: Schilling fullname: Schilling, Megan A. – sequence: 10 givenname: Sarah A. surname: Jenkins fullname: Jenkins, Sarah A. – sequence: 11 givenname: Karen S. surname: Corson fullname: Corson, Karen S. – sequence: 12 givenname: Nicholas J. surname: Martin fullname: Martin, Nicholas J. – sequence: 13 givenname: Andrew G. surname: Letizia fullname: Letizia, Andrew G. – sequence: 14 givenname: Robert D. surname: Hontz fullname: Hontz, Robert D. – sequence: 15 givenname: Peifang surname: Sun fullname: Sun, Peifang |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38077368$$D View this record in MEDLINE/PubMed |
BookMark | eNp9Ul1vFCEUnZgaW2v_gA-GR19mBe7AwuO6qbaxtklXfSXMcKdh3YF1YI37l_orZT9sjA8SEi7ccw7hcF5WJyEGrKrXjE4AlH7X-2HYTDjlMGFcSsX1s-qMSdnUwHlz8ld9Wl2ktKRlNBoAxIvqFBSdTkGqs-pxFrJvo_OYSI5kwYmLg_WBxJ4sZveLeh6_1Zyktf-OZD3GjKVX5ufocAyWDPe3M_LTdp0PNqMjadMuscupFCnvdOxBf1s7XGNwGDK5_UQ6XK3qAZ3fk3Y70m1zzPGX73zeEvtQuCmTu8F3Ywzk_WzCXlXPe7tKeHFcz6uvHy6_zK_qm7uP1_PZTd01DHKtVE9ZrwQoQNtTCY4y2wDVSFvJUHKmOIqulY3QGqZTAdC6VmhQrLSchvPq-qDrol2a9egHO25NtN7sD-L4YOyYfbdCwxFEL-mUo6INlcx2WlhFrWCNdsyKovX2oFWs-7HBlM3g0-65NmDcJMM15VoAh6ZA3xyhm7Y483Txn78qAH4AFEdSGrF_gjBqdpkw-0yYXSbMMROFpP4hFX9t9jHk0frV_6i_Afj0u6k |
CitedBy_id | crossref_primary_10_3390_vaccines13030262 crossref_primary_10_1002_jmv_29585 crossref_primary_10_3389_fimmu_2025_1535014 |
Cites_doi | 10.1126/science.abn8652 10.1001/jamanetworkopen.2023.10650 10.1093/infdis/jiad054 10.1101/2022.04.30.489997 10.15585/mmwr.mm7112e1 10.1126/scitranslmed.abm2311 10.7554/eLife.06054 10.1126/science.abn7760 10.1038/s41467-022-33378-7 10.1128/CVI.00230-14 10.1016/j.it.2019.01.005 10.1038/s41467-020-16638-2 10.1038/s41392-021-00759-1 10.1016/j.ijid.2021.11.040 10.1002/eji.202149470 10.1126/science.abn8863 10.1038/s41541-021-00393-6 10.1038/s41586-021-04385-3 10.1038/s41598-018-36972-2 10.1016/j.vaccine.2021.05.063 10.3389/fimmu.2021.637651 10.1016/j.isci.2022.105202 10.1126/scitranslmed.abi9215 10.3201/eid2607.200841 10.4049/jimmunol.174.4.2185 10.1056/NEJMc2119912 10.1016/j.jviromet.2017.06.007 10.1038/s41591-021-01377-8 10.1038/s41586-021-04386-2 10.1371/journal.pone.0248007 10.3389/fimmu.2020.576622 10.1126/science.abj3321 10.1016/S0022-1759(98)00170-7 10.1016/j.cell.2022.06.005 10.1097/QAD.0000000000001200 10.1016/j.celrep.2021.109929 10.1080/22221751.2020.1815591 10.1002/smll.202200836 10.1016/j.cell.2021.03.028 10.1038/s41591-021-01678-y 10.1016/j.lana.2022.100297 10.1016/j.chom.2021.06.001 10.1038/s41423-021-00778-6 10.1073/pnas.2107249118 10.7554/eLife.83710.sa2 10.1016/j.celrep.2021.110114 10.1038/s41467-021-21968-w 10.1128/mBio.02473-21 10.1016/j.cell.2020.02.058 10.1038/s41577-020-0402-6 10.4049/jimmunol.1201574 10.3389/fimmu.2021.737083 10.1016/j.chom.2021.03.005 10.1016/j.jim.2016.11.005 10.1128/spectrum.01837-22 10.1038/s41586-022-04399-5 10.1056/NEJMc2212117 10.1038/nm.3443 10.1016/j.lfs.2020.118056 10.1126/science.abb2507 10.1126/science.abm3425 10.1089/08892220260387940 10.1073/pnas.2217590120 10.1093/infdis/jiac319 10.1001/jamanetworkopen.2022.54777 10.1038/s41591-020-0913-5 10.1016/j.cell.2020.05.015 10.1038/s41586-020-2598-9 10.1016/j.xcrm.2021.100329 |
ContentType | Journal Article |
Copyright | Copyright © 2023 Balinsky, Jiang, Jani, Cheng, Zhang, Belinskaya, Qiu, Long, Schilling, Jenkins, Corson, Martin, Letizia, Hontz and Sun. |
Copyright_xml | – notice: Copyright © 2023 Balinsky, Jiang, Jani, Cheng, Zhang, Belinskaya, Qiu, Long, Schilling, Jenkins, Corson, Martin, Letizia, Hontz and Sun. |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 DOA |
DOI | 10.3389/fimmu.2023.1266829 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic Directory of Open Access Journals |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic CrossRef |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Biology |
EISSN | 1664-3224 |
ExternalDocumentID | oai_doaj_org_article_2e35f6072e804061ac95a80a5149d1a5 38077368 10_3389_fimmu_2023_1266829 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | 53G 5VS 9T4 AAFWJ AAKDD AAYXX ACGFO ACGFS ACXDI ADBBV ADRAZ AENEX AFPKN ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BCNDV CITATION DIK EBS EMOBN GROUPED_DOAJ GX1 HYE KQ8 M48 M~E OK1 PGMZT RNS RPM CGR CUY CVF ECM EIF IAO IEA IHR IHW IPNFZ NPM RIG 7X8 |
ID | FETCH-LOGICAL-c413t-88f01f85383eaf063d01a4309e0b61e62182e5cb64599377533bdb59381218d93 |
IEDL.DBID | DOA |
ISSN | 1664-3224 |
IngestDate | Wed Aug 27 01:27:53 EDT 2025 Thu Jul 10 23:25:06 EDT 2025 Wed Feb 19 02:11:02 EST 2025 Thu Apr 24 23:01:15 EDT 2025 Tue Jul 01 03:33:40 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Keywords | Omicron BA.1 SARS-CoV-2 Moderna mRNA vaccine ADCC IgG subclass S2 |
Language | English |
License | Copyright © 2023 Balinsky, Jiang, Jani, Cheng, Zhang, Belinskaya, Qiu, Long, Schilling, Jenkins, Corson, Martin, Letizia, Hontz and Sun. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c413t-88f01f85383eaf063d01a4309e0b61e62182e5cb64599377533bdb59381218d93 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
OpenAccessLink | https://doaj.org/article/2e35f6072e804061ac95a80a5149d1a5 |
PMID | 38077368 |
PQID | 2902953234 |
PQPubID | 23479 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_2e35f6072e804061ac95a80a5149d1a5 proquest_miscellaneous_2902953234 pubmed_primary_38077368 crossref_primary_10_3389_fimmu_2023_1266829 crossref_citationtrail_10_3389_fimmu_2023_1266829 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2023-00-00 |
PublicationDateYYYYMMDD | 2023-01-01 |
PublicationDate_xml | – year: 2023 text: 2023-00-00 |
PublicationDecade | 2020 |
PublicationPlace | Switzerland |
PublicationPlace_xml | – name: Switzerland |
PublicationTitle | Frontiers in immunology |
PublicationTitleAlternate | Front Immunol |
PublicationYear | 2023 |
Publisher | Frontiers Media S.A |
Publisher_xml | – name: Frontiers Media S.A |
References | Haslwanter (B67) 2021; 12 Chen (B13) 2020; 20 Tuekprakhon (B27) 2022; 185 Li (B10) 2021; 18 Tejedor Vaquero (B49) 2021; 12 Morrison (B57) 2017; 248 Excler (B34) 2014; 21 Yates (B51) 2021; 2 Izadi (B53) 2023; 120 Cao (B26) 2022; 608 Wang (B64) 2021; 12 Jegaskanda (B40) 2013; 190 Mannar (B24) 2022; 375 Ma (B55) 2022; 18 Damelang (B52) 2019; 40 Silva (B62) 2023; 12 Frey (B44) 1998; 221 Hagemann (B41) 2022; 52 Zolla-Pazner (B33) 2016; 30 Kleanthous (B8) 2021; 6 Wei (B31) 2023; 6 Yu (B16) 2021; 6 Kallolimath (B54) 2021; 118 Cao (B22) 2022; 602 Sun (B42) 2017; 441 Duan (B2) 2020; 11 Kaplonek (B48) 2022 Tenforde (B46) 2022; 71 Pajon (B47) 2022; 386 McCallum (B19) 2022; 375 Amanat (B39) 2020; 26 Sun (B29) 2023; 228 Stowe (B32) 2022; 13 Sternberg (B3) 2020; 257 Prompetchara (B56) 2021; 16 DiLillo (B35) 2014; 20 Hsieh (B66) 2021; 37 Petro (B36) 2015; 4 Zhou (B63) 2022; 14 Yin (B21) 2022; 375 Poh (B9) 2020; 11 Gilbert (B5) 2022; 375 Banks (B58) 2002; 18 McCallum (B69) 2021; 184 Wrapp (B4) 2020; 367 Braun (B15) 2020; 587 Petersen (B37) 2022; 114 Pinto (B11) 2021; 373 Skarbinski (B45) 2022; 12 Sun (B60) 2022; 25 Menegale (B30) 2023; 6 Khoury (B7) 2021; 27 Shah (B18) 2021; 12 Carreno (B23) 2022; 602 Grifoni (B14) 2020; 181 Sun (B43) 2019; 9 Gomez-Roman (B59) 2005; 174 Walls (B1) 2020; 181 Cameroni (B20) 2022; 602 Tauzin (B61) 2021; 29 Earle (B6) 2021; 39 Kato (B38) 2022; 227 Yi (B12) 2020; 9 Farkash (B50) 2021; 37 Hachmann (B28) 2022; 387 VanBlargan (B25) 2022; 28 Vangeti (B65) 2022; 10 Cerutti (B68) 2021; 29 Nisreen (B17) 2020; 26 |
References_xml | – volume: 375 year: 2022 ident: B19 article-title: Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement publication-title: Science doi: 10.1126/science.abn8652 – volume: 6 year: 2023 ident: B30 article-title: Evaluation of waning of SARS-CoV-2 vaccine-induced immunity: A systematic review and meta-analysis publication-title: JAMA Netw Open doi: 10.1001/jamanetworkopen.2023.10650 – volume: 228 year: 2023 ident: B29 article-title: Antibody responses to the SARS-CoV-2 ancestral strain and omicron variants in moderna mRNA-1273 vaccinated active-duty U.S. Navy sailors and marines publication-title: J Infect Dis doi: 10.1093/infdis/jiad054 – volume: 608 year: 2022 ident: B26 article-title: BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection publication-title: Nature doi: 10.1101/2022.04.30.489997 – volume: 71 year: 2022 ident: B46 article-title: Effectiveness of mRNA vaccination in preventing COVID-19-associated invasive mechanical ventilation and death - United States, March 2021-January 2022 publication-title: MMWR Morb Mortal Wkly Rep doi: 10.15585/mmwr.mm7112e1 – year: 2022 ident: B48 article-title: mRNA-1273 and BNT162b2 COVID-19 vaccines elicit antibodies with differences in Fc-mediated effector functions publication-title: Sci Transl Med doi: 10.1126/scitranslmed.abm2311 – volume: 4 year: 2015 ident: B36 article-title: Herpes simplex type 2 virus deleted in glycoprotein D protects against vaginal, skin and neural disease publication-title: Elife doi: 10.7554/eLife.06054 – volume: 375 year: 2022 ident: B24 article-title: SARS-CoV-2 Omicron variant: Antibody evasion and cryo-EM structure of spike protein-ACE2 complex publication-title: Science doi: 10.1126/science.abn7760 – volume: 13 start-page: 5736 year: 2022 ident: B32 article-title: Effectiveness of COVID-19 vaccines against Omicron and Delta hospitalisation, a test negative case-control study publication-title: Nat Commun doi: 10.1038/s41467-022-33378-7 – volume: 21 year: 2014 ident: B34 article-title: Nonneutralizing functional antibodies: a new "old" paradigm for HIV vaccines publication-title: Clin Vaccine Immunol doi: 10.1128/CVI.00230-14 – volume: 40 start-page: 197 year: 2019 ident: B52 article-title: Role of IgG3 in infectious diseases publication-title: Trends Immunol doi: 10.1016/j.it.2019.01.005 – volume: 11 start-page: 2806 year: 2020 ident: B9 article-title: Two linear epitopes on the SARS-CoV-2 spike protein that elicit neutralising antibodies in COVID-19 patients publication-title: Nat Commun doi: 10.1038/s41467-020-16638-2 – volume: 6 start-page: 346 year: 2021 ident: B16 article-title: Antibody-dependent cellular cytotoxicity response to SARS-CoV-2 in COVID-19 patients publication-title: Signal Transduct Target Ther doi: 10.1038/s41392-021-00759-1 – volume: 114 year: 2022 ident: B37 article-title: Emergence of new SARS-CoV-2 Variant of Concern Omicron (B.1.1.529) - highlights Africa's research capabilities, but exposes major knowledge gaps, inequities of vaccine distribution, inadequacies in global COVID-19 response and control efforts publication-title: Int J Infect Dis doi: 10.1016/j.ijid.2021.11.040 – volume: 52 year: 2022 ident: B41 article-title: Natural killer cell-mediated ADCC in SARS-CoV-2-infected individuals and vaccine recipients publication-title: Eur J Immunol doi: 10.1002/eji.202149470 – volume: 375 year: 2022 ident: B21 article-title: Structures of the Omicron spike trimer with ACE2 and an anti-Omicron antibody publication-title: Science doi: 10.1126/science.abn8863 – volume: 6 start-page: 128 year: 2021 ident: B8 article-title: Scientific rationale for developing potent RBD-based vaccines targeting COVID-19 publication-title: NPJ Vaccines doi: 10.1038/s41541-021-00393-6 – volume: 602 year: 2022 ident: B22 article-title: Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies publication-title: Nature doi: 10.1038/s41586-021-04385-3 – volume: 9 start-page: 1109 year: 2019 ident: B43 article-title: NK cells activated through antibody-dependent cell cytotoxicity and armed with degranulation/IFN-gamma production suppress antibody-dependent enhancement of dengue viral infection publication-title: Sci Rep doi: 10.1038/s41598-018-36972-2 – volume: 39 year: 2021 ident: B6 article-title: Evidence for antibody as a protective correlate for COVID-19 vaccines publication-title: Vaccine doi: 10.1016/j.vaccine.2021.05.063 – volume: 12 year: 2021 ident: B18 article-title: The case for S2: the potential benefits of the S2 subunit of the SARS-CoV-2 spike protein as an immunogen in fighting the COVID-19 pandemic publication-title: Front Immunol doi: 10.3389/fimmu.2021.637651 – volume: 25 start-page: 105202 year: 2022 ident: B60 article-title: Asymptomatic or symptomatic SARS-CoV-2 infection plus vaccination confers increased adaptive immunity to variants of concern publication-title: iScience doi: 10.1016/j.isci.2022.105202 – volume: 14 year: 2022 ident: B63 article-title: A human antibody reveals a conserved site on beta-coronavirus spike proteins and confers protection against SARS-CoV-2 infection publication-title: Sci Transl Med doi: 10.1126/scitranslmed.abi9215 – volume: 26 year: 2020 ident: B17 article-title: Severe acute respiratory syndrome Coronavirus 2–specific antibody responses in coronavirus disease 2019 patients publication-title: Emerg Infect Dis J doi: 10.3201/eid2607.200841 – volume: 174 year: 2005 ident: B59 article-title: Vaccine-elicited antibodies mediate antibody-dependent cellular cytotoxicity correlated with significantly reduced acute viremia in rhesus macaques challenged with SIVmac251 publication-title: J Immunol doi: 10.4049/jimmunol.174.4.2185 – volume: 386 year: 2022 ident: B47 article-title: SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination publication-title: N Engl J Med doi: 10.1056/NEJMc2119912 – volume: 248 start-page: 7 year: 2017 ident: B57 article-title: Antibody-dependent NK cell degranulation as a marker for assessing antibody-dependent cytotoxicity against pandemic 2009 influenza A(H1N1) infection in human plasma and influenza-vaccinated transchromosomic bovine intravenous immunoglobulin therapy publication-title: J Virol Methods doi: 10.1016/j.jviromet.2017.06.007 – volume: 27 year: 2021 ident: B7 article-title: Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection publication-title: Nat Med doi: 10.1038/s41591-021-01377-8 – volume: 602 year: 2022 ident: B20 article-title: Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift publication-title: Nature doi: 10.1038/s41586-021-04386-2 – volume: 16 year: 2021 ident: B56 article-title: DNA vaccine candidate encoding SARS-CoV-2 spike proteins elicited potent humoral and Th1 cell-mediated immune responses in mice publication-title: PloS One doi: 10.1371/journal.pone.0248007 – volume: 11 year: 2020 ident: B2 article-title: The SARS-CoV-2 spike glycoprotein biosynthesis, structure, function, and antigenicity: implications for the design of spike-based vaccine immunogens publication-title: Front Immunol doi: 10.3389/fimmu.2020.576622 – volume: 373 year: 2021 ident: B11 article-title: Broad betacoronavirus neutralization by a stem helix-specific human antibody publication-title: Science doi: 10.1126/science.abj3321 – volume: 221 start-page: 35 year: 1998 ident: B44 article-title: A statistically defined endpoint titer determination method for immunoassays publication-title: J Immunol Methods doi: 10.1016/S0022-1759(98)00170-7 – volume: 185 start-page: 2422 year: 2022 ident: B27 article-title: Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum publication-title: Cell doi: 10.1016/j.cell.2022.06.005 – volume: 30 year: 2016 ident: B33 article-title: Non-neutralizing antibody functions for protection and control HIV in humans and SIV and SHIV in non-human primates publication-title: AIDS doi: 10.1097/QAD.0000000000001200 – volume: 37 start-page: 109929 year: 2021 ident: B66 article-title: Stabilized coronavirus spike stem elicits a broadly protective antibody publication-title: Cell Rep doi: 10.1016/j.celrep.2021.109929 – volume: 9 year: 2020 ident: B12 article-title: Functional mapping of B-cell linear epitopes of SARS-CoV-2 in COVID-19 convalescent population publication-title: Emerg Microbes Infect doi: 10.1080/22221751.2020.1815591 – volume: 18 start-page: e2200836 year: 2022 ident: B55 article-title: SARS-CoV-2 spike stem protein nanoparticles elicited broad ADCC and robust neutralization against variants in mice publication-title: Small doi: 10.1002/smll.202200836 – volume: 184 start-page: 2332 year: 2021 ident: B69 article-title: N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2 publication-title: Cell doi: 10.1016/j.cell.2021.03.028 – volume: 28 year: 2022 ident: B25 article-title: An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies publication-title: Nat Med doi: 10.1038/s41591-021-01678-y – volume: 12 start-page: 100297 year: 2022 ident: B45 article-title: Risk of severe clinical outcomes among persons with SARS-CoV-2 infection with differing levels of vaccination during widespread Omicron (B.1.1.529) and Delta (B.1.617.2) variant circulation in Northern California: A retrospective cohort study publication-title: Lancet Reg Health Am doi: 10.1016/j.lana.2022.100297 – volume: 29 start-page: 1137 year: 2021 ident: B61 article-title: A single dose of the SARS-CoV-2 vaccine BNT162b2 elicits Fc-mediated antibody effector functions and T cell responses publication-title: Cell Host Microbe doi: 10.1016/j.chom.2021.06.001 – volume: 18 year: 2021 ident: B10 article-title: A novel linear and broadly neutralizing peptide in the SARS-CoV-2 S2 protein for universal vaccine development publication-title: Cell Mol Immunol doi: 10.1038/s41423-021-00778-6 – volume: 118 year: 2021 ident: B54 article-title: Highly active engineered IgG3 antibodies against SARS-CoV-2 publication-title: Proc Natl Acad Sci U.S.A. doi: 10.1073/pnas.2107249118 – volume: 12 year: 2023 ident: B62 article-title: Identification of a conserved S2 epitope present on spike proteins from all highly pathogenic coronaviruses publication-title: Elife doi: 10.7554/eLife.83710.sa2 – volume: 37 start-page: 110114 year: 2021 ident: B50 article-title: Anti-SARS-CoV-2 antibodies elicited by COVID-19 mRNA vaccine exhibit a unique glycosylation pattern publication-title: Cell Rep doi: 10.1016/j.celrep.2021.110114 – volume: 12 start-page: 1715 year: 2021 ident: B64 article-title: A conserved immunogenic and vulnerable site on the coronavirus spike protein delineated by cross-reactive monoclonal antibodies publication-title: Nat Commun doi: 10.1038/s41467-021-21968-w – volume: 12 year: 2021 ident: B67 article-title: A combination of receptor-binding domain and N-terminal domain neutralizing antibodies limits the generation of SARS-CoV-2 spike neutralization-escape mutants publication-title: mBio doi: 10.1128/mBio.02473-21 – volume: 181 start-page: 281 year: 2020 ident: B1 article-title: Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein publication-title: Cell doi: 10.1016/j.cell.2020.02.058 – volume: 20 year: 2020 ident: B13 article-title: T cell responses in patients with COVID-19 publication-title: Nat Rev Immunol doi: 10.1038/s41577-020-0402-6 – volume: 190 year: 2013 ident: B40 article-title: Cross-reactive influenza-specific antibody-dependent cellular cytotoxicity antibodies in the absence of neutralizing antibodies publication-title: J Immunol doi: 10.4049/jimmunol.1201574 – volume: 12 year: 2021 ident: B49 article-title: The mRNA-1273 vaccine induces cross-variant antibody responses to SARS-CoV-2 with distinct profiles in individuals with or without pre-existing immunity publication-title: Front Immunol doi: 10.3389/fimmu.2021.737083 – volume: 29 start-page: 819 year: 2021 ident: B68 article-title: Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite publication-title: Cell Host Microbe doi: 10.1016/j.chom.2021.03.005 – volume: 441 start-page: 24 year: 2017 ident: B42 article-title: NK cell degranulation as a marker for measuring antibody-dependent cytotoxicity in neutralizing and non-neutralizing human sera from dengue patients publication-title: J Immunol Methods doi: 10.1016/j.jim.2016.11.005 – volume: 10 start-page: e0183722 year: 2022 ident: B65 article-title: Serum Fc-mediated monocyte phagocytosis activity is stable for several months after SARS-CoV-2 asymptomatic and mildly symptomatic infection publication-title: Microbiol Spectr doi: 10.1128/spectrum.01837-22 – volume: 602 year: 2022 ident: B23 article-title: Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron publication-title: Nature doi: 10.1038/s41586-022-04399-5 – volume: 387 year: 2022 ident: B28 article-title: Neutralization escape by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4, and BA.5 publication-title: N Engl J Med doi: 10.1056/NEJMc2212117 – volume: 20 year: 2014 ident: B35 article-title: Broadly neutralizing hemagglutinin stalk-specific antibodies require FcgammaR interactions for protection against influenza virus in vivo publication-title: Nat Med doi: 10.1038/nm.3443 – volume: 257 start-page: 118056 year: 2020 ident: B3 article-title: Structural features of coronavirus SARS-CoV-2 spike protein: Targets for vaccination publication-title: Life Sci doi: 10.1016/j.lfs.2020.118056 – volume: 367 year: 2020 ident: B4 article-title: Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation publication-title: Science doi: 10.1126/science.abb2507 – volume: 375 start-page: 43 year: 2022 ident: B5 article-title: Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial publication-title: Science doi: 10.1126/science.abm3425 – volume: 18 year: 2002 ident: B58 article-title: Sustained antibody-dependent cell-mediated cytotoxicity (ADCC) in SIV-infected macaques correlates with delayed progression to AIDS publication-title: AIDS Res Hum Retroviruses doi: 10.1089/08892220260387940 – volume: 120 start-page: e2217590120 year: 2023 ident: B53 article-title: Subclass-switched anti-spike IgG3 oligoclonal cocktails strongly enhance Fc-mediated opsonization publication-title: Proc Natl Acad Sci U.S.A. doi: 10.1073/pnas.2217590120 – volume: 227 year: 2022 ident: B38 article-title: Memory B cell development after asymptomatic or mild symptomatic SARS-CoV-2 infection publication-title: J Infect Dis doi: 10.1093/infdis/jiac319 – volume: 6 start-page: e2254777 year: 2023 ident: B31 article-title: Estimation of vaccine effectiveness of CoronaVac and BNT162b2 against severe outcomes over time among patients with SARS-CoV-2 omicron publication-title: JAMA Netw Open doi: 10.1001/jamanetworkopen.2022.54777 – volume: 26 year: 2020 ident: B39 article-title: A serological assay to detect SARS-CoV-2 seroconversion in humans publication-title: Nat Med doi: 10.1038/s41591-020-0913-5 – volume: 181 start-page: 1489 year: 2020 ident: B14 article-title: Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals publication-title: Cell doi: 10.1016/j.cell.2020.05.015 – volume: 587 year: 2020 ident: B15 article-title: SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19 publication-title: Nature doi: 10.1038/s41586-020-2598-9 – volume: 2 start-page: 100329 year: 2021 ident: B51 article-title: Serological analysis reveals an imbalanced IgG subclass composition associated with COVID-19 disease severity publication-title: Cell Rep Med doi: 10.1016/j.xcrm.2021.100329 |
SSID | ssj0000493335 |
Score | 2.3561027 |
Snippet | Vaccination with the primary two-dose series of SARS-CoV-2 mRNA protects against infection with the ancestral strain, and limits the presentation of severe... |
SourceID | doaj proquest pubmed crossref |
SourceType | Open Website Aggregation Database Index Database Enrichment Source |
StartPage | 1266829 |
SubjectTerms | ADCC Antibody-Dependent Cell Cytotoxicity COVID-19 - prevention & control Humans IgG subclass Immunoglobulin G Killer Cells, Natural Moderna mRNA vaccine Omicron BA.1 RNA, Messenger SARS-CoV-2 Spike Glycoprotein, Coronavirus - genetics |
SummonAdditionalLinks | – databaseName: Scholars Portal Journals: Open Access dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1bi9QwFA7riuCLeHe8EcE36ZgmTad5EOkuLouyI-w4sm8lTdKlum3WaUd2_pK_0nPSzoDg-iT0oW1yeslJ-L4TkvMR8loEoaMEgpyqEhCg2DLKrHRRyY0WygHih0DxZJ4eL5OPZ_Jsj2zljsYG7P4a2qGe1HJ1Mb36sXkPA_4dRpyAt2-rumnWU9QBn8aANxlXN8hNQKYZSjmcjHT_28CGhRBy2Dtzjekf-BTS-F_PPQMGHd0ld0bySPPB2_fInmvvk1uDnOTmAfmVt31delwXSHtPF5xa30DkT31FF_npIjr0XyNOu8v6u6MhQQOUwTHooWnanM5z-lMbU7fAQC3t1iXO0nRwEnZZUT08fxNtpXN7Ov9Ece4_CjtQ0AivqNn0vvdXtQGOT_U52HY9_dzg4r-WHuTT-CFZHn34cngcjVoMkQGY66Msq1hcAbZnwukKeI1lsU4EU46VaexSTATvpCkxNw0wHgiCRGlLqYAQQJFV4hHZb33rnhBqNOM2BdoptEvkjGXWpSqVQtrUOsHshMRbDxRmTFSOehkXBQQs6LUieK1ArxWj1ybkzc7mckjT8c_aB-jYXU1MsR1u-NV5MY7Ygjshq5TNuMsYsh5tlNQZ08AwlY21nJBX225RwJDE1tWt8-uu4IpxJQUXyYQ8HvrL7lWY338m0uzp__iEZ-Q2_tYwI_Sc7PertXsBHKkvX4aO_xt0fQ0l priority: 102 providerName: Scholars Portal |
Title | Antibodies to S2 domain of SARS-CoV-2 spike protein in Moderna mRNA vaccinated subjects sustain antibody-dependent NK cell-mediated cell cytotoxicity against Omicron BA.1 |
URI | https://www.ncbi.nlm.nih.gov/pubmed/38077368 https://www.proquest.com/docview/2902953234 https://doaj.org/article/2e35f6072e804061ac95a80a5149d1a5 |
Volume | 14 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1di9QwFA2yIPgifjt-EcE36WzaNJ3ksbu4LsqOsOPKvJU0SaWrbRebEecv-Su9N-mM-6K-CCW0TdOmvbecc0NyLiGveEh0lEOQ0zQcAhRbJ9IKl9SZ0Vw5QPwQKJ4ti9OL_N1arK-l-sI5YVEeOH64w8xx0RRskTnJEHy0UUJLpgHolU11UC8FzLsWTF1G3ss5F3GVDERh6rBpu24zx2Th8xRASQZO-RuJgmD_n1lmQJuTO-T2RBNpGbt3l9xw_T1yMyaO3N4nP8vet_WAMwCpH-gqo3boIManQ0NX5fkqOR4-JRkdr9ovjgYpBqiDLWY-07Q7X5b0uzam7YFrWjpuahyPGWEnrKeiOt5_m-yS5Hq6fE9xlD8Ja02wER5Rs_WDH360Btg81Z-h7ejphw6n-fX0qJynD8jFyZuPx6fJlHUhMQBoPpGyYWkDKC650w0wGMtSnXOmHKuL1BUo-e6EqVGFBrgNhDu8trVQAP1QZRV_SA76oXePCTWaZbYAgsm1y8WCSesKVQgubGEdZ3ZG0p0FKjNJkmNmjK8VhCZotSpYrUKrVZPVZuT1vs1VFOT469VHaNj9lSimHU6Ai1WTi1X_crEZeblziwp-Pvy6unfDZqwyxTIleMbzGXkU_WX_KFTyX_BCPvkfXXhKbuFrxbGfZ-TAf9u458CGfP0iOD6Ub9cplGe5_AUThQXC |
linkProvider | Directory of Open Access Journals |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Antibodies+to+S2+domain+of+SARS-CoV-2+spike+protein+in+Moderna+mRNA+vaccinated+subjects+sustain+antibody-dependent+NK+cell-mediated+cell+cytotoxicity+against+Omicron+BA.1&rft.jtitle=Frontiers+in+immunology&rft.au=Corey+A.+Balinsky&rft.au=Le+Jiang&rft.au=Vihasi+Jani&rft.au=Ying+Cheng&rft.date=2023&rft.pub=Frontiers+Media+S.A&rft.eissn=1664-3224&rft.volume=14&rft_id=info:doi/10.3389%2Ffimmu.2023.1266829&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_2e35f6072e804061ac95a80a5149d1a5 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1664-3224&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1664-3224&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1664-3224&client=summon |